Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.
Non-Profit Trusted Source of Non-Commercial Health Information
Scientists have been working to understand the mystery behind supercentenarians for decades, now researchers may have overcome one of the first obstacles in cracking that secret code to living a long and healthy life of 110+ years. Longevity warriors for some reason appear to be resistant to diseases such as cancer, heart disease, and Alzheimer’s …
The FDA has announced that it is lifting the hold and cleared ImStem’s investigational drug IMS001 which utilizes AgeX’s pluripotent stem cell technology ESI-053, thus it will be allowed to be made available for the treatment of multiple sclerosis in clinical trial settings. “Since pluripotent stem cells are capable of differentiating into all human cell …
The San Diego based biotech Epirium has raised $85 million to pursue anti-aging approaches to slow down, delay, or reverse the process of aging, led by Longitude Capital and ARCH Venture Partners to advance clinical trial of their drug candidate which will be initially tested in Becker muscular dystrophy. Aging is similar to muscular dystrophy …
Lineage Cell Therapeutics and AgeX Therapeutics have been awarded a United States Patent and Trademark Office patent for “Methods Of Reprogramming Animal Somatic Cells.” “The issuance of this patent highlights Lineage’s dominant position in the field of cell therapy,” stated Brian M. Culley, CEO of Lineage. “Our efforts to develop new treatments rely on well-characterized …
The UK biotech Juvenescence is valued at $500 million, and it will use public offering to move 5 life extension technologies into phase 2 trials; the biotech incubator is creating medical therapies to increase human longevity. Recently the company has moved its IPO to the second half of 2020, the postponement from an earlier public …
Anti-aging focused life sciences companies Juvenescence and AgeX have published an encouraging progress report in Regenerative Medicine regarding the development of hypoimmunogenic/universal allogeneic cells. Autologous cell therapy uses a patient’s own cells, while allogeneic cell therapy uses donor cells. Using an allogeneic approach is superior in quality, scalability, manufacturing cost, commercialisation, and much more. However, …